Comparative bioavailability of a newly developed Irbesartan 300 mg containing preparation

• Main Authors: Petrov Andrey D. (Author), Gatchev Emil M. (Author), Kalinov Krasimir B. (Author), Filipova Elena P. (Author), Uzunova Katya H. (Author), Vekov Toni Y. (Author)
• Format: Book
• Published: Srpsko lekarsko drustvo, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Irbesartan (CAS registry: 138402-11-6) is a potent, orally active, selective antagonist of the angiotensin II receptors (type AT1) indicated for the treatment of arterial hypertension and chronic heart failure. Aim: The objective of the present study was to demonstrate the bioequivalen...